{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:50Z","timestamp":1772165690155,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fresenius Medical Care Renal Therapies Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Elevated serum phosphorus concentrations are common among maintenance hemodialysis patients. Protein is a major source of dietary phosphate, but restriction of protein intake can result in hypoalbuminemia and protein-energy wasting. We hypothesized that sucroferric oxyhydroxide (SO), a potent phosphate binder with a low pill burden, may reduce serum phosphorus levels in hemodialysis patients with hypoalbuminemia without adversely impacting albumin levels or dietary intake of protein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively examined de-identified data from 79 adult, in-center hemodialysis patients with baseline hypoalbuminemia (\u2264 3.5\u2009g\/dL) switched to SO as part of routine clinical care for at least 1\u2009year. Temporal changes (3-month intervals from baseline through Q4) in phosphate binder pill burden, serum phosphorous levels, nutritional markers, and equilibrated Kt\/V were analyzed. Data from a matched reference group of non-hypoalbuminemic patients (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200979) switched to SO were also examined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SO therapy was associated with a mean reduction of 45.7 and 45.1% in daily phosphate binder pill burden, and a mean reduction of 0.4\u2009mg\/dL and 0.51\u2009mg\/dL in serum phosphorus levels for the hypoalbuminemic and non-hypoalbuminemic patients, respectively. Hypoalbuminemic patients demonstrated significant increases in mean serum albumin levels from 3.50\u2009mg\/dL at baseline to 3.69, 3.74, 3.70, and 3.69\u2009mg\/dL during Q1 through Q4, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), whereas serum albumin levels remained unchanged in the non-hypoalbuminemic group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both hypoalbuminemic and non-hypoalbuminemic patients switching to SO exhibited significant reductions in serum phosphorus concentrations and daily phosphate binder pill burden. Among hypoalbuminemic patients, the initiation of SO therapy was also associated with increases in serum albumin, suggesting therapy may have allowed patients to increase their dietary intake of protein.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-019-1582-9","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T16:44:43Z","timestamp":1572453883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda H.","family":"Ficociello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidhya","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaos V.","family":"Athienites","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudy","family":"Mullon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Kossmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9786-5235","authenticated-orcid":false,"given":"Daniel W.","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"1582_CR1","unstructured":"US-DOPPS (Dialysis Outcomes and Practice Patterns Study) Practice Monitor. Serum phosphorous (most recent). April 2019. \n                    https:\/\/www.dopps.org\/DPM\/Files\/phosphmgdl_c_overallTAB.htm\n                    \n                  . Accessed 8 July 2019."},{"issue":"11","key":"1582_CR2","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.2215\/CJN.03780411","volume":"6","author":"E Zitt","year":"2011","unstructured":"Zitt E, Lamina C, Sturm G, et al. Interaction of time-varying albumin and phosphorus on mortality in incident dialysis patients. Clin J Am Soc Nephrol. 2011;6(11):2650\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1582_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.cca.2017.09.005","volume":"474","author":"Y Hou","year":"2017","unstructured":"Hou Y, Li X, Sun L, Qu Z, Jiang L, Du Y. Phosphorus and mortality risk in end-stage renal disease: a meta-analysis. Clin Chim Acta. 2017;474:108\u201313.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"1582_CR4","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3945\/ajcn.2008.26665","volume":"88","author":"CS Shinaberger","year":"2008","unstructured":"Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88(6):1511\u20138.","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"1582_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.2215\/CJN.04620510","volume":"6","author":"KE Lynch","year":"2011","unstructured":"Lynch KE, Lynch R, Curhan GC, Brunelli SM. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(3):620\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1582_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cqn.2014.03.003","volume":"3","author":"A Sinha","year":"2014","unstructured":"Sinha A, Prasad N. Dietary management of hyperphosphatemia in chronic kidney disease. Clinical Queries: Nephrology. 2014;3(1):38\u201345.","journal-title":"Clinical Queries: Nephrology"},{"key":"1582_CR7","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1046\/j.1523-1755.63.s84.20.x","volume":"84","author":"GA Kaysen","year":"2003","unstructured":"Kaysen GA, Don BR. Factors that affect albumin concentration in dialysis patients and their relationship to vascular disease. Kidney Int Suppl. 2003;84:S94\u20137.","journal-title":"Kidney Int Suppl"},{"key":"1582_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/1471-2369-14-242","volume":"14","author":"NR Sridhar","year":"2013","unstructured":"Sridhar NR, Josyula S. Hypoalbuminemia in hemodialyzed end stage renal disease patients: risk factors and relationships\u2013a 2 year single center study. BMC Nephrol. 2013;14:242.","journal-title":"BMC Nephrol"},{"issue":"7","key":"1582_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.2215\/CJN.13141216","volume":"12","author":"R Eriguchi","year":"2017","unstructured":"Eriguchi R, Obi Y, Streja E, et al. Longitudinal associations among renal urea clearance-corrected normalized protein catabolic rate, serum albumin, and mortality in patients on hemodialysis. Clin J Am Soc Nephrol. 2017;12(7):1109\u201317.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1582_CR10","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.2215\/CJN.07690910","volume":"6","author":"U Feroze","year":"2011","unstructured":"Feroze U, Noori N, Kovesdy CP, et al. Quality-of-life and mortality in hemodialysis patients: roles of race and nutritional status. Clin J Am Soc Nephrol. 2011;6(5):1100\u201311.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1582_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.jrn.2016.01.009","volume":"26","author":"L Gutekunst","year":"2016","unstructured":"Gutekunst L. An update on phosphate binders: a dietitian's perspective. J Ren Nutr. 2016;26(4):209\u201318.","journal-title":"J Ren Nutr"},{"issue":"6","key":"1582_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.jrn.2018.04.002","volume":"28","author":"BT Lodebo","year":"2018","unstructured":"Lodebo BT, Shah A, Kopple JD. Is it important to prevent and treat protein-energy wasting in chronic kidney disease and chronic dialysis patients? J Ren Nutr. 2018;28(6):369\u201379.","journal-title":"J Ren Nutr"},{"issue":"1","key":"1582_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.ajkd.2014.01.429","volume":"64","author":"D Fouque","year":"2014","unstructured":"Fouque D, Horne R, Cozzolino M, Kalantar-Zadeh K. Balancing nutrition and serum phosphorus in maintenance dialysis. Am J Kidney Dis. 2014;64(1):143\u201350.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"1582_CR14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1080\/14656566.2018.1491548","volume":"19","author":"SM Sprague","year":"2018","unstructured":"Sprague SM, Floege J. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother. 2018;19(10):1137\u201348.","journal-title":"Expert Opin Pharmacother"},{"key":"1582_CR15","unstructured":"Velphoro (sucroferric oxyhydroxide) [package insert]. Waltham, MA: Fresenius Medical Care North America; 2018. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/205109s006lbl.pdf"},{"issue":"11","key":"1582_CR16","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/ndt\/gfw460","volume":"32","author":"J Floege","year":"2017","unstructured":"Floege J, Covic AC, Ketteler M, et al. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant. 2017;32(11):1918\u201326.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"1582_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5414\/CN109021","volume":"88","author":"DW Coyne","year":"2017","unstructured":"Coyne DW, Ficociello LH, Parameswaran V, et al. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: a retrospective analysis of pharmacy data. Clin Nephrol. 2017;88(8):59\u201367.","journal-title":"Clin Nephrol"},{"issue":"3","key":"1582_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000487856","volume":"47","author":"K Kalantar-Zadeh","year":"2018","unstructured":"Kalantar-Zadeh K, Parameswaran V, Ficociello LH, et al. Real-world scenario improvements in serum phosphorus levels and pill burden in peritoneal dialysis patients treated with sucroferric oxyhydroxide. Am J Nephrol. 2018;47(3):153\u201361.","journal-title":"Am J Nephrol"},{"issue":"6","key":"1582_CR19","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","volume":"30","author":"J Floege","year":"2015","unstructured":"Floege J, Covic AC, Ketteler M, et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015;30(6):1037\u201346.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1582_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10157-016-1299-z","volume":"21","author":"F Koiwa","year":"2017","unstructured":"Koiwa F, Terao A. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, phase II study [published correction appears in Clin Exp Nephrol. 2017;21(3):523]. Clin Exp Nephrol. 2017;21(3):513\u201322.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"1582_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/nep.12891","volume":"22","author":"F Koiwa","year":"2017","unstructured":"Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study. Nephrology (Carlton). 2017;22(4):293\u2013300.","journal-title":"Nephrology (Carlton)"},{"issue":"5","key":"1582_CR22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s11255-017-1774-9","volume":"50","author":"D Xie","year":"2018","unstructured":"Xie D, Ye N, Li M. A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients. Int Urol Nephrol. 2018;50(5):905\u20139.","journal-title":"Int Urol Nephrol"},{"key":"1582_CR23","unstructured":"Velphoro (sucroferric oxyhydroxide) [product monograph]. St. Gallen, Switzerland: Vifor Fresenius Medical Care Renal Pharma Ltd.; 2018. \n                    https:\/\/pdf.hres.ca\/dpd_pm\/00043058.PDF"},{"issue":"9","key":"1582_CR24","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1093\/ndt\/gfh941","volume":"20","author":"K Kalantar-Zadeh","year":"2005","unstructured":"Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005;20(9):1880\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1582_CR25","first-page":"318","volume":"34","author":"H Komaba","year":"2019","unstructured":"Komaba H, Kakuta T, Wada T, Hida M, Suga T, Fukagawa M. Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate. Nephrol Dial Transplant. 2019;34(2):318\u201325.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"1582_CR26","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.ekir.2019.06.002","volume":"4","author":"FC Barreto","year":"2019","unstructured":"Barreto FC, Barreto DV, Massy ZA, Dr\u00fceke TB. Strategies for phosphate control in patients with CKD. Kidney Int Rep. 2019;4(8):1043\u201356.","journal-title":"Kidney Int Rep"},{"key":"1582_CR27","doi-asserted-by":"crossref","unstructured":"Kaysen GA. Serum albumin concentration in dialysis patients: why does it remain resistant to therapy? Kidney Int. 2003;(suppl 87):S92\u20138.","DOI":"10.1046\/j.1523-1755.64.s87.14.x"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1582-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1582-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1582-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T20:05:50Z","timestamp":1603829150000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1582-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1582-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.13440\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13440\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13440\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"23 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This manuscript reports data from a retrospective analysis. The need for informed consent was waived by the New England Institutional Review Board (Needham, Massachusetts) because of the anonymous and purely observational nature of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LHF, VP, CM, and RJK are employees of Fresenius Medical Care Renal Therapies Group. LHF, CM, and RJK own stock in Fresenius Medical Care North America. RJK is on the Board of Directors of Advanced Renal Technologies. DWC is a consultant and speaker for Fresenius Medical Care. KK-Z has received honoraria and\/or support from Abbott, AbbVie, Alexion, American Society of Nephrology, Amgen, AstraZeneca, AVEO, Chugai, DaVita, Fresenius, Fresenius Kabi, Genentech, Haymarket Media, Hofstra Medical School, Hospira, International Federation of Kidney Foundations, International Society for Hemodialysis, International Society of Renal Nutrition and Metabolism, Japanese Society for Dialysis Therapy, Keryx, National Institutes of Health, National Kidney Foundation, Novartis, OPKO, Pfizer, Relypsa, Resverlogix, Sandoz, Sanofi, Shire, UpToDate, Vifor, and ZS Pharma. NVA received honoraria for advisory boards from Fresenius Medical Care and Mallinckrodt and is a speaker for Mallinckrodt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"396"}}